Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. According to a a definitive agreement between the companies, Apricus Biosciences Inc - APRI - will acquire Topotarget USA, who owns Totect (Dexrazoxane HCl), the only drug approved by the FDA to treat a potentially serious complication of cancer therapy—the leakage of chemotherapy drugs from veins into surrounding tissues.

Tags: Apricus APRI Nasdaq:APRI Dexrazoxane